Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-06-10
2008-07-22
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S085000, C544S224000, C530S399000
Reexamination Certificate
active
07402557
ABSTRACT:
The present invention relates to compositions and methods for treating the epithelial toxicity caused by administering to a human cancer patient an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition preferably comprises an EGFR inhibitor and a keratinocyte growth factor (KGF) in a pharmaceutically-acceptable carrier. The method of treatment comprises co-administering to the patient a therapeutically effective amount of KGF with the EGFR inhibitor.
REFERENCES:
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5760041 (1998-06-01), Wissner et al.
patent: 94/23032 (1994-10-01), None
patent: 9625422 (1996-08-01), None
patent: 96/34614 (1996-11-01), None
Rodeck et al. J. Cell Sci. 110: 113-121, 1997.
Pollack et al. J. Pharmacol. Experim. Therap. 291(2): 739-748, 1999.
Adjei, Alex. Drugs of the Future. 26(11): 1087-1092, 2001.
Kelloff et al. Cancer Epidemiology, Biomarkers and Prevention. 5: 657-666, 1996.
Modjtahedi et al. International Journal of Oncology 13: 335-342, 1998.
Siu et al. American Society of Clinical Oncology, Abstract # 1498, 1999 ASCO Annual Meeting.
Abstract Woodburn, J.R. et al. “ZD1839 An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development” Asbtract only XP-001009911 dated 1997.
Driscoll, D. et al. “Effect Of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 On Vascular Endothelial Growth Factor Secretion From Several Tumor Models” Abstract only XP-001014746 dated 1999.
Liu et al. Am. J. Pathol. 153(1): 263-269, 1998.
Ishiwata et al. Am. J. Pathol. 153(1): 213-222, 1998.
Watanabe et al. Pathol. Internat. 50(5): 363-372, 2000.
Yang et al. “Eradication of Established-Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy”Cancer Research(1999) vol. 59, pp. 1236-1243.
Jones et al. “New EGF-R Selective Tyrosine Kinase Inhibitor Reveals Variable Growth Responses in Prostate Carcinoma Cell Lines PC-3 and DU-145”Int. J. Cancer(1997) vol. 71, pp. 1010-1018.
Groene, L., et al., “Structure-Function Relationships for the EGF/TGF-α Family of Mitogens”Growth Factors11 (1994), pp. 235-257.
Wikner, N., et al. “Transforming Growth Factory-β Stimulates the Expression of Fibronectin by Human Keratinocytes”J. Invest. Dermatology91 (1988), pp. 207-212.
Yoneda, A., et al., “Engineering of an FGF-proteoglycan Fusion Protein with Heparin-independent, Mitogenic Activity”Nature Biotech. 18 (2000) pp. 641-644.
Hsu, E., et al., “Enhanced Stability of Recombinant Keratinocyte Growth Factor by Mutagenesis”Protein Engineering, Design & Selection19 (2006) pp. 147-153.
Ross, E. “Pharmacodynamis: Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect” in:Goodman & Gilman's The Pharmacological Basis of Therapeutics(New York, McGraw-Hill, 1996), pp. 29-31.
Miller Penelope Elizabeth
Moyer James Dale
Ladas & Parry
Saoud Christine J
LandOfFree
Combined treatment with keratinocyte growth factor and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined treatment with keratinocyte growth factor and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined treatment with keratinocyte growth factor and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967841